NDAORALTABLET
Approved
Jul 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRISORALEN (trioxsalen) is an oral psoralen approved in 1964 for photochemotherapy indications, used in combination with UVA light exposure. It is a small-molecule photosensitizing agent that enhances skin response to controlled ultraviolet radiation. The drug treats conditions such as vitiligo, psoriasis, and other dermatologic disorders requiring photoactivation.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely consolidating focus on retained market segments rather than expanding market share.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRISORALEN offers limited career growth potential with zero linked job openings and an approaching LOE lifecycle. Roles in this product focus on managing legacy dermatology revenue and maintaining customer relationships in a niche market rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on TRISORALEN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.